Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-cancer therapeutics - Halozyme

Next Previous
Drug Profile

Research programme: anti-cancer therapeutics - Halozyme

Alternative Names: HTI-1511; PEG NME8058; PEG NME8062; PEG-ADA2; PEG-ADA2-E182T; PEG-ADA2-K374D; PEG-ADA2-R222Q-S265N; PEGylated adenosine deaminase 2

Latest Information Update: 12 Nov 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Halozyme Therapeutics
  • Class Auristatins; Enzymes; Immunoconjugates
  • Mechanism of Action Adenosine deaminase stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Discontinued Cholangiocarcinoma; Chronic lymphocytic leukaemia; Colorectal cancer; Lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 04 Nov 2019 Discontinued - Preclinical for Cholangiocarcinoma in USA (unspecified route) due to organisational restructuring
  • 04 Nov 2019 Discontinued - Preclinical for Chronic lymphocytic leukaemia in USA (unspecified route) due to organisational restructuring
  • 04 Nov 2019 Discontinued - Preclinical for Colorectal cancer in USA (unspecified route) due to organisational restructuring

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top